m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02176)
Name
LY-2484595
Synonyms
Evacetrapib; Evacetrapib (LY2484595); Evacetrapib (USAN); Evacetrapib [USAN:INN]; IHIUGIVXARLYHP-YBXDKENTSA-N; LY 2484595; LY-2484595; LY2484595; SCHEMBL108367; SCHEMBL108602; SCHEMBL141340; Tube726; evacetrapib-ly2484595; (1S,4r)-4-(((S)-5-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)cyclohexanecarboxylic acid; 1186486-62-3; 51XWV9K850; AK172427; C31H36F6N6O2; CHEMBL2017179; EX-A621; GTPL8401; HMS3651J12; KS-000007CQ; UNII-51XWV9K850
    Click to Show/Hide
Status
Phase 3
Structure
Formula
C31H36F6N6O2
InChI
1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
InChIKey
IHIUGIVXARLYHP-UXNJHFGPSA-N
PubChem CID
49836058
INTEDE Drug ID
DR1878
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
References
Ref 1 Methylation of adenosine at the N(6) position post-transcriptionally regulates hepatic P450s expression. Biochem Pharmacol. 2020 Jan;171:113697. doi: 10.1016/j.bcp.2019.113697. Epub 2019 Nov 7.
Ref 2 Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98. doi: 10.1080/00498250310001602775.